The Celltrion’s biosimilar product ‘Remsima’acquired the drug price registration in Japan
The Celltrion’s biosimilar product ‘Remsima’has been registered in Japan.
Remsima has been included in the Japanese ‘Reported Items, Sinkit Product List’ (expected to be registered in 11 November 2014).The selecteddrug price is JPY 59.814 (100mg1).
The drug was omitted from the price registrati...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
